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Study Objective. To determine the influence of Echinacea purpurea on the
pharmacokinetics of lopinavir-ritonavir and on cytochrome P450 (CYP) 3A and
P-glycoprotein activity by using the probe substrates midazolam and
fexofenadine, respectively.
Design. Open-label, single-sequence pharmacokinetic study.
Setting. Outpatient clinic in a federal government research center.
Subjects. Thirteen healthy volunteers (eight men, five women).
Intervention. Subjects received lopinavir 400 mg–ritonavir 100 mg twice/day with
meals for 29.5 days. On day 16, subjects received E. purpurea 500 mg 3
times/day for 28 days: 14 days in combination with lopinavir-ritonavir and 14
days of E. purpurea alone. In order to assess CYP3A and P-glycoprotein activity,
subjects received single oral doses of midazolam 8 mg and fexofenadine 120 mg,
respectively, before and after the 28 days of E. purpurea.
Measurements and Main Results. On days 15 and 30 of lopinavir-ritonavir
administration (before and after E. purpurea administration, respectively), serial
blood samples were collected over 12 hours to determine lopinavir and
ritonavir concentrations and subsequent pharmacokinetic parameters by using
noncompartmental methods. Neither lopinavir nor ritonavir pharmacokinetics
were significantly altered by 14 days of E. purpurea coadministration. The post-
echinacea:pre-echinacea geometric mean ratios (GMRs) for lopinavir area
under the concentration-time curve (AUC) from 0–12 hours and for maximum
concentration were 0.96 (90% confidence interval [CI] 0.83–1.10, p=0.82) and
1.00 (90% CI 0.88–1.12, p=0.72), respectively. Conversely, GMRs for
midazolam AUC from time zero extrapolated to infinity and oral clearance
were 0.73 (90% CI 0.61–0.85, p=0.008) and 1.37 (90% CI 1.10–1.63, p=0.02),
respectively. Fexofenadine pharmacokinetics did not significantly differ before
and after E. purpurea administration (p>0.05).
Conclusion. Echinacea purpurea induced CYP3A activity but did not alter lopinavir
concentrations, most likely due to the presence of the potent CYP3A inhibitor,
ritonavir. Echinacea purpurea is unlikely to alter the pharmacokinetics of ritonavir-
boosted protease inhibitors but may cause modest decreases in plasma
concentrations of other CYP3A substrates.
KeyWords: human immunodeficiency virus, HIV, protease inhibitors, lopinavir, ritonavir,
Echinacea purpurea, herb, cytochrome P450, CYP, P-glycoprotein, P-gp, drug interaction.
(Pharmacotherapy 2010;30(8):797–805)
Despite the success of potent combination anti-
retroviral therapy, complementary and alternative
medicines (CAM) remain widely used by patients
with human immunodeficiency virus (HIV)
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infection. Indeed, more than half of HIV-infected
patients report using CAM at some point in
time.1–4 Patients with HIV infection typically use
CAM for symptomatic relief of adverse effects
secondary to antiretroviral therapy and/or for
general health benefits. Unfortunately, the
coadministration of CAM and antiretroviral
drugs can place patients at risk for clinically
significant drug-drug interactions. Because HIV
protease inhibitors are primarily metabolized by
cytochrome P450 (CYP) 3A4, herbal preparations
that modulate this metabolic pathway have the
potential to alter protease inhibitor pharmaco-
kinetics, potentially resulting in reduced
antiretroviral efficacy or increased toxicity.1 One
group of authors found that St. John’s wort
decreased the systemic exposure of the HIV
protease inhibitor indinavir by 57% during
coadministration.5 In another study by the same
investigators, 3 weeks of garlic caplet supplemen-
tation decreased the area under the concentration-
time curve (AUC) of saquinavir, another HIV
protease inhibitor, by 51%.6
In spite of the potential for clinically relevant
interactions between CAM and antiretrovirals,
relatively few herbal products have been tested
for their effects on antiretroviral drug disposition
in vivo; one such herbal supplement that has not
been assessed for its influence on antiretroviral
pharmacokinetics is Echinacea purpurea. Echinacea
purpurea is predominantly used to prevent or treat
the common cold, influenza, and upper respiratory
tract infections.7–9 In the setting of HIV infection,
E. purpurea may be taken for its immunomodu-
latory and antiviral effects.1 Of note, E. purpurea
products ranked behind garlic as the second top-
selling herbal dietary supplement in the food,
drug, and mass market channel in the United
States in 2005, with over $21 million in sales.10
At least two studies have assessed the influence
of E. purpurea on CYP3A activity in humans.11, 12
Using single doses of both oral and intravenous
midazolam as a probe for intestinal and hepatic
CYP3A activity, respectively, one group of authors
observed an 85% increase in the intestinal avail-
ability of midazolam (p=0.015) and a 15% reduction
in the hepatic availability of the drug (p=0.006)
after 1600 mg (total daily dose) of E. purpurea root
administration for 8 days.11 These data suggest
that E. purpurea selectively alters the catalytic
activity of CYP3A in the liver versus intestine.
Conversely, another study found that 28 days of
E. purpurea whole plant extract administration
did not significantly alter CYP3A metabolic
serum 1-hydroxymidazolam:midazolam ratios
collected 1 hour after dosing in 12 healthy
volunteers.12
To this end, it is difficult to predict the influence
of E. purpurea on the pharmacokinetics of CYP3A
substrates such as the HIV protease inhibitors.
The presence or absence of such interactions may
depend on the relative extraction of the coadmin-
istered drug by hepatic and intestinal CYP3A.
Due to the potentially serious consequences of a
drug-drug interaction between E. purpurea and
HIV protease inhibitors (i.e., virologic and/or
immunologic failure or drug toxicity), this study
was designed to assess the influence of E.
purpurea on the steady-state pharmacokinetics of
lopinavir plus ritonavir in healthy volunteers.
Methods
Study Design and Setting
This single-center, open-label study evaluated
the effect of 14 days of orally administered E.
purpurea on the steady-state pharmacokinetics of
lopinavir and ritonavir in healthy volunteers
(Figure 1). In addition, subjects underwent
phenotyping for CYP3A and P-glycoprotein (P-
gp) activity by taking oral midazolam and
fexofenadine, respectively, before and after 28
days of E. purpurea administration. This study
was conducted at the Clinical Research Center at
the National Institutes of Health (Bethesda, MD).
Subjects
Healthy male and female volunteers aged
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18–50 years were eligible for participation in this
study. Each study candidate underwent an
evaluation that included a medical history,
physical examination, and laboratory analysis
(serum electrolyte levels, liver function tests,
cholesterol and triglyceride levels) to rule out
any medical conditions that could place subjects
at risk or potentially affect study results. Subjects
were also required to have a negative HIV enzyme-
linked immunoabsorbent assay test. No drugs,
including prescription and nonprescription drugs,
herbal supplements, and oral contraceptives, were
allowed to be taken by the subjects within 30
days of study participation. Additional exclusion
criteria included current or recent (within 6 wks)
tobacco use, drug or alcohol abuse, history of
intolerance to any of the study drugs, and
persistent diarrhea. Acetaminophen, ibuprofen,
and loperamide were allowed as needed to treat
adverse effects associated with the study drugs;
however, subjects were prohibited from taking
these drugs on pharmacokinetic sampling days.
Subjects were also instructed to refrain from
ingesting fruit juices, including grapefruit juice,
throughout the study period. Pregnant or
breastfeeding women were excluded from study
participation, and women of childbearing
potential were required to use a nonhormonal
method of contraception throughout the study.
Informed consent was obtained from all study
participants, and clinical research was conducted
in accordance with guidelines for human experi-
mentation as specified by the U.S. Department of
Health and Human Services. The study was
approved by the National Institute of Allergy and
Infectious Diseases Institutional Review Board.
Treatment Protocol and Blood Sampling
Subjects were given a single oral dose of
midazolam syrup 8 mg (Roche Laboratories,
Nutley, NJ) and fexofenadine 120 mg (two 60-mg
tablets; Sanofi-Aventis, Bridgewater, NJ) together
on an empty stomach. Blood samples were
collected for determination of midazolam and
fexofenadine in plasma at time 0 (before dosing)
and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, and 24
hours after dosing. After collection, samples
were centrifuged immediately and plasma
harvested and frozen at −80°C until analysis.
Between 7 and 28 days after midazolam and
fexofenadine administration, subjects began
taking lopinavir 400 mg–ritonavir 100 mg (two
tablets of Kaletra [lopinavir 200 mg–ritonavir 50
mg/tablet]; Abbott Laboratories, North Chicago,
IL) twice/day with meals for a total of 29.5 days
(days 1–30.5). On day 15 of lopinavir-ritonavir
administration, subjects received their morning
dose with food in the clinic, followed by blood
sample collection for the determination of
steady-state lopinavir and ritonavir plasma
concentrations (phase 1). Blood samples were
collected immediately before the dose and 0.5, 1,
2, 3, 4, 6, 8 and 12 hours after the dose. The
next morning, subjects began taking E. purpurea
500 mg (two 250-mg capsules of Echinamide;
Natural Factors Nutritional Products, Inc.,
Everett, WA) 3 times/day while continuing
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8 mg and fexofenadine 120 mg
administered; plasma samples
collected over next 24 hoursa
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Figure 1. Timeline of the study design. aPlasma samples were collected for determination of fexofenadine and midazolam
concentrations used in the pharmacokinetic analyses. bPlasma samples were collected for the determination of steady-state
lopinavir and ritonavir concentrations used in pharmacokinetic analyses.
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lopinavir-ritonavir twice/day. After 14 days of
lopinavir-ritonavir and E. purpurea coadminis-
tration, subjects returned to the clinic for repeat
lopinavir-ritonavir pharmacokinetic sampling
(study day 30, phase 2) as performed in phase 1.
After phase 2 pharmacokinetic sampling, subjects
discontinued lopinavir-ritonavir and continued
taking E. purpurea alone for an additional 14
days.
After a total of 28 days of taking E. purpurea,
subjects returned to the clinic for repeat
fexofenadine and midazolam administration with
postdose blood sampling performed as described
earlier. Blood was also collected for end-of-study
safety monitoring, including a chemistry panel,
complete blood count, pregnancy test, and
nonfasting cholesterol and triglyceride levels.
Analytic Methods
Lopinavir and ritonavir plasma concentrations
were determined by high-performance liquid
chromatography with liquid-liquid extraction by
using a method developed in our laboratory.13
Calibration curves for lopinavir and ritonavir
were linear from 0.050–15.0 µg/ml (R2 ≥ 0.0997).
Percent errors, as a measure of accuracy, were less
than 15%, and the respective inter- and intraassay
coefficients of variation for ritonavir were
5.70–10.74% and 2.91–10.59%, whereas those of
lopinavir were 4.07–9.08% and 3.16–9.36%,
respectively, at four different concentrations. The
limit of quantitation was 0.050 µg/ml, and the
limit of detection was 0.030 µg/ml.
Fexofenadine and midazolam were separated
with use of ultra-performance liquid chromato-
graphy with detection by tandem mass spec-
trometry using multiple reaction monitoring, as
previously described.13 Calibration curves for
midazolam and fexofenadine were linear from
1.0–100 ng/ml (R2 ≥ 0.998). Percent errors, as a
measure of accuracy, were less than 15%, and the
inter- and intraassay coefficients of variation were
1.31–8.48% and 3.53–6.03%, respectively, at
three different drug concentrations. The limit of
quantitation was 1.0 ng/ml, and the limit of
detection was 0.20 ng/ml.
Echinacea purpurea Formulation
Echinacea purpurea fresh liquid extract 8:1
(250-mg) softgel capsules from a single lot of
Echinamide were used in this investigation.
Concentrated extracts from freshly harvested E.
purpurea plants contained standardized amounts
of alkylamides 0.25 mg/ml, polysaccharides 25.5
mg/ml, and cichoric acid 2.5 mg/ml by using a
patented extraction method.14 The product was
manufactured in accordance with United States
Pharmacopeia guidelines. The Echinamide
formulation used in this study did not undergo
independent analysis by an outside laboratory.
Pharmacokinetic Analysis
Plasma concentrations of lopinavir, ritonavir,
fexofenadine, and midazolam were analyzed by
noncompartmental methods with WinNonlin
pharmacokinetic software, version 5.0 (Pharsight
Corp., Mountain View, CA). The maximum
plasma concentration (Cmax) and time to reach
Cmax (Tmax) were obtained by direct inspection of
the plasma concentration–time profiles. The
elimination rate constant (z) was determined by
calculating the absolute value of the slope of the
log-linear regression using at least three points
on the plasma concentration–time plot. The
AUC over 0–12 hours (AUC0–12) at steady state
was determined for lopinavir and ritonavir by
using the log-linear trapezoidal rule. Apparent
oral clearance at steady state (Cl/Fss, where F is
bioavailability) for lopinavir and ritonavir was
obtained by dividing the dose by AUC0–12 at
steady state. For fexofenadine and midazolam,
the AUC from time zero to the last quantifiable
concentration (AUC0–t(last)) was determined by
the log-linear trapezoidal rule; the AUC from
time zero extrapolated to infinity (AUC0–∞) was
calculated by dividing the last measured
concentration by z and adding this value to
AUCt(last). Apparent oral clearance (Cl/F) was
estimated for midazolam and fexofenadine as
dose/AUC0–∞.
Statistical Analysis
Results are expressed as geometric mean values
and coefficients of variation, defined as
(SD/mean) x 100%. Comparisons between
treatments are displayed as geometric mean ratios
(GMR) and 90% confidence intervals (CIs).
Pharmacokinetic parameter values for lopinavir,
ritonavir, midazolam, and fexofenadine at
baseline (phase 1) and after E. purpurea
administration (phase 2) were compared by using
a two-tailed, paired, Student t test, except for
Tmax, which was analyzed with the use of the
Wilcoxon signed rank test. A p value of less than
0.05 was considered to indicate a statistically
significant difference for all analyses. SYSTAT
software, version 11 (Systat Software, Inc.,
Chicago, IL) was used for statistical comparisons;
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Microsoft Excel 2003 (Microsoft Corp., Redmond,
WA) was used to generate descriptive data.
A difference in lopinavir AUC of at least 35%
was considered to be clinically relevant for the
purpose of estimating sample size. A standard
deviation of 0.40 was assumed for lopinavir AUC
based on previous data.15 With  set at 0.05, a
sample of 13 subjects was deemed necessary to
provide 80% power to detect a 35% difference in
lopinavir AUC before and after E. purpurea
administration (SYSTAT software, version 11).
Results
Subjects
Fourteen subjects were enrolled, and 13 (eight
men, five women) completed study participation.
One subject dropped out before study completion,
citing personal reasons, and no data were avail-
able to report for this individual. Demographic data
for the study participants are presented in Table
1. Study subjects reported 100% adherence to
the lopinavir-ritonavir dosing schedule except for
two subjects who reported missing single doses
of lopinavir-ritonavir during the study. However,
none of the missed doses occurred within 72
hours of pharmacokinetic sampling. No missed
doses of E. purpurea were reported. Adherence to
lopinavir-ritonavir and E. purpurea was further
confirmed by pill counts and by determination of
plasma concentrations of lopinavir and ritonavir,
which were comparable to previously reported
data in healthy volunteers.16
Lopinavir and Ritonavir
Neither lopinavir nor ritonavir pharmacokinetic
parameter values were significantly altered after
14 days of E. purpurea administration (Table 2,
Figure 2). The post-echinacea:pre-echinacea
GMRs for lopinavir AUC0–12 and Cmax were 0.96
(90% CI 0.83–1.10, p=0.82) and 1.00 (90% CI
0.88–1.12, p=0.72), respectively.
Midazolam and Fexofenadine
Midazolam AUC0–∞ and Cl/F were significantly
decreased and increased, respectively, after E.
purpurea administration (Table 3, Figure 3). The
GMRs for midazolam AUC0–∞ and Cl/F were 0.73
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Table 1. Demographics of the 13 Healthy Volunteers
Age Body Mass
(yrs)/ Weight Index
Sex Race-Ethnicity (kg) (kg/m2)
26/M Caucasian 86 24.4
40/M Caucasian 92 28.1
22/M Caucasian 89 26.5
48/F Caucasian 51 20.0
40/M Caucasian 88 27.9
33/M African-American 87 28.1
30/F Caucasian 57 21.4
31/F Caucasian, Hispanic 51 22.4
23/F Caucasian 67 21.8
23/F Caucasian, Hispanic 94 38.4
36/M Caucasian, Hispanic 75 26.1
45/M Caucasian 78 24.4
31/M Caucasian 86 28.6
Median age 31 yrs, weight 86 kg, body mass index 26 kg/m2.
Table 2. Lopinavir and Ritonavir Pharmacokinetic Parameters Before and After 14 days of Echinacea purpurea Extract
Administration in the 13 Healthy Volunteers
Pre-Echinacea Coefficient of Post-Echinacea Coefficient of Post-Echinacea:Pre-Echinacea
Geometric Variation Geometric Variation Geometric Mean Ratio
Parameter Mean (%) Mean (%) (90%CI) p Valuea
Lopinavir
AUC0–12
(µg•hr/ml) 109 42 105 48 0.96 (0.83–1.10) 0.82
Cmax (µg/ml) 11.9 33 12.0 42 1.00 (0.88–1.12) 0.72
Tmax (hrs)b 2.0 0–6 2.0 0.5–4 0.94
Half-life (hrs) 8.7 48 9.5 46 1.09 (0.29–1.38) 0.62
Cl/Fss (L/hr) 3.66 36 3.80 39 1.04 (0.90–1.18) 0.59
Ritonavir
AUC0–12
(µg•hr/ml) 7.39 75 6.79 125 0.92 (0.66–1.18) 0.76
Cmax (µg/ml) 1.03 68 1.01 136 0.98 (0.67–1.29) 0.53
Tmax (hrs)b 2.9 0–6 1.8 0–4 0.14
Half-life (hrs) 3.97 64 5.3 36 1.35 (0.49–2.20) 0.17
Cl/Fss (L/hr) 13.53 53 14.70 60 1.09 (0.86–1.31) 0.32
CI = confidence interval; AUC0–12 = area under the concentration-time curve from 0–12 hrs; Cmax = maximum plasma concentration; Tmax =
time to reach Cmax; Cl/Fss = apparent oral clearance at steady state, where F is bioavailability.
aThe Student paired, two-tailed t test was used for statistical comparisons except for Tmax, for which the Wilcoxon signed rank test was used.
bData for Tmax are median and range values.
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(90% CI 0.61–0.85, p=0.008) and 1.37 (90% CI
1.10–1.63, p=0.02), respectively. The GMR for
midazolam half-life was 0.55 (90% CI 0.40–0.70,
p=0.051), which bordered on statistical significance.
Midazolam Cmax and Tmax were not significantly
altered after E. purpurea administration (p>0.05).
In contrast to midazolam, fexofenadine pharmaco-
kinetic parameter values showed no significant
difference before and after E. purpurea adminis-
tration (p>0.05 for all comparisons; Table 3).
Safety
Twelve of the 13 subjects experienced an adverse
event consistent with those expected of the study
drugs. All of the adverse events were mild to
moderate in severity, and no serious adverse
events were reported. Grades 1 and 2 diarrhea,
abdominal pain, and nausea were the most
frequently reported adverse events; these events
were comparable in frequency and severity in
both phases of the study (lopinavir-ritonavir
alone [phase 1], and lopinavir-ritonavir with E.
purpurea coadministration [phase 2]). One
subject reported conjunctivitis, sinus congestion,
and acute sore throat (all grade 1), which were
not believed to be related to the study drugs.
There were no significant laboratory abnormalities
throughout the study.
Discussion
The use of herbal supplements continues to be
common among HIV-infected patients. Studies
conducted previously have shown that concurrent
use of certain herbal preparations, such as St.
John’s wort and garlic, can significantly decrease
plasma concentrations of unboosted protease
inhibitors.5, 6 However, ritonavir-boosted protease
inhibitor regimens are now preferred over
regimens containing a single protease inhibitor;
as a result, we chose to study the influence of E.
purpurea on the pharmacokinetics of the
commonly used protease inhibitor combination,
lopinavir-ritonavir.17 In addition to studying the
influence of E. purpurea on lopinavir-ritonavir,
we also chose to study the isolated effects of E.
purpurea on CYP3A and P-gp activity (using the
probe substrates midazolam and fexofenadine,
respectively) since previous studies in healthy
volunteers and in vitro demonstrated conflicting
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Table 3. Midazolam and Fexofenadine Pharmacokinetic Parameter Values Before and After 28 days of Echinacea purpurea
Extract Administration in 13 Healthy Volunteers
Pre-Echinacea Coefficient of Post-Echinacea Coefficient of Post-Echinacea:Pre-Echinacea
Geometric Variation Geometric Variation Geometric Mean Ratio
Parameter Mean (%) Mean (%) (90%CI) p Valuea
Midazolam
AUC0–∞
(ng•hr/ml) 143 35 104 43 0.73 (0.61–0.85) 0.008
Cmax (ng/ml) 50 31 38 44 0.77 (0.58–0.96) 0.14
Tmax (hrs)b 0.5 0.5–1.0 0.5 0.5–1.5 0.44
Half-life (hrs) 5.6 74 3.1 51 0.55 (0.40–0.70) 0.051
Cl/Fss (ml/hr) 56 37 77 57 1.37 (1.10–1.63) 0.02
Fexofenadine
AUC0–∞
(ng•hr/ml) 1569 55 1543 39 0.98 (0.82–1.14) 0.46
Cmax (ng/ml) 256 58 232 43 0.91 (0.77–1.04) 0.18
Tmax (hrs)b 2.0 1.5–3.5 2.0 1.0–8.0 0.31
Half-life (hrs) 5.6 18 5.5 16 0.97 (0.90–1.04) 0.46
Cl/Fss (ml/hr) 76 52 78 42 1.02 (0.88–1.16) 0.75
CI = confidence interval; AUC = area under the concentration-time curve; Cmax = maximum plasma concentration; Tmax = time to reach Cmax;
Cl/Fss = apparent oral clearance at steady state where F is bioavailability.
aThe Student paired, two-tailed t test was used for statistical comparisons except for Tmax, for which the Wilcoxon signed rank test was used.
bData for Tmax are median and range values.
Figure 2. Steady-state lopinavir concentration versus time
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results.11, 12, 18, 19
In our investigation, we did not observe signi-
ficant changes in the pharmacokinetic profiles of
lopinavir or ritonavir after 14 days of E. purpurea
exposure, nor did we see changes in fexofenadine
pharmacokinetics after 28 days of E. purpurea
administration (Tables 2 and 3); however, we did
see a modest but statistically significant decrease
in midazolam exposure (−27%, p=0.008) and an
increase in midazolam Cl/F (37%, p=0.02). The
midazolam half-life was reduced by 45% after E.
purpurea administration, which trended toward
statistical significance (p=0.051). Of note, Cmax
and Tmax were not significantly altered by E.
purpurea administration. These results suggest
induction of the CYP3A-mediated metabolism of
midazolam by E. purpurea.
Induction of CYP3A by E. purpurea has been
previously described in a study involving healthy
volunteers.11 In that study, contrasting modulatory
effects of E. purpurea were observed at hepatic
and intestinal sites (i.e., induction and inhibition,
respectively). Both intravenous and oral midazolam
were used in that study to differentiate intestinal
versus hepatic effects of E. purpurea on CYP3A
activity, and the investigators observed a signifi-
cant increase in the oral availability of midazolam
(~43%, p=0.028) and a significant decrease in
hepatic availability (~15%, p=0.015). Of note, no
significant changes were observed in midazolam
pharmacokinetic parameter values after oral
administration before and after 8 days of E.
purpurea 400 mg 4 times/day.
In contrast to the above-mentioned study, we
studied the effects of E. purpurea only on oral
midazolam pharmacokinetics; thus, our results
are reflective of the net effect of E. purpurea on
both intestinal and hepatic CYP3A activity. It is
interesting that, after oral midazolam adminis-
tration, we observed results consistent with net
CYP3A induction by E. purpurea, whereas the
authors of the previous study11 observed no
significant change in midazolam pharmaco-
kinetics. Perhaps this is because subjects
undergoing CYP3A phenotyping in our study
received E. purpurea for 28 days compared with
an 8-day course in the previous investigation.
The longer duration of E. purpurea administration
in our study may have allowed for induction of
hepatic CYP3A to predominate over intestinal
CYP3A inhibition, resulting in a net increase in
overall CYP3A activity. However, since we did
not administer intravenous midazolam in our
study, it is not possible to definitively conclude
that intestinal and hepatic CYP3A were differen-
tially affected by E. purpurea.
Although our results are consistent with those
of the above-mentioned study11 in that we both
observed CYP3A modulation with E. purpurea
administration, another group of investigators
found no effect of E. purpurea 800 mg twice/day
for 28 days on CYP3A activity using a 1-hour
postdose plasma concentration ratio of 1-
hydroxymidazolam:midazolam to determine
CYP3A phenotype (after an oral 8-mg midazolam
dose).12 Of note, both studies administered a
similar daily dose of E. purpurea of 1600 mg
versus 1500 mg in our study, and the same dose
of oral midazolam of 8 mg. Possible reasons for
the disparity in results between our study and
this other study12 include different E. purpurea
manufacturers (potentially resulting in different
amounts of phytochemicals [i.e., alkylamides]
responsible for CYP3A modulation) and
dissimilar CYP3A phenotyping methods, which
included use of a single postdose plasma concen-
tration ratio of 1-hydroxymidazolam: midazolam
in that study compared with use of midazolam
AUC0–∞ in our investigation.12, 20
Despite observing enhanced CYP3A activity
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after 28 days of E. purpurea administration, we
did not observe reductions in the CYP3A
substrates lopinavir and ritonavir after 14 days of
E. purpurea dosing. The most likely explanation
for our results is that ritonavir, a potent intestinal
and hepatic CYP3A inhibitor, masked the
CYP3A-inducing effects of E. purpurea, resulting
in the absence of a drug interaction.21 Indeed
low-dose ritonavir 100 mg twice/day is capable of
attenuating CYP3A induction associated with
other CYP3A inducers, such as rifabutin and
efavirenz.22, 23 Although it cannot be ruled out
that E. purpurea induced the metabolism of
midazolam and not lopinavir-ritonavir due to the
shorter course of E. purpurea administration
between lopinavir-ritonavir sampling periods
compared with that of midazolam (14 vs 28
days), this seems unlikely, as 14 days of E.
purpurea administration should have been
sufficient to produce some degree of CYP3A
induction even if maximal induction was not
achieved. Indeed, other investigators observed
CYP3A induction with E. purpurea after only 8
days of administration to healthy volunteers.11
Despite in vitro reports suggesting that E.
purpurea may inhibit intestinal P-gp and alter the
bioavailability of orally administered substrates,
we did not observe any alteration in P-gp activity
after 28 days of E. purpurea administration, using
fexofenadine as a P-gp probe substrate.19, 24
However, it should be noted that fexofenadine
lacks specificity as a P-gp probe in that it is also
transported by organic anion transporting
polypeptides (OATP) including OATP1B1,
OATP1A2, OATP1B3, and OATP2B1.25 Still, our
results are consistent with those of previous
investigators who did not observe a significant
effect of E. purpurea administration (267 mg 3
times/day for 14 days) on P-gp activity using
digoxin as their P-gp probe drug.26 To this end, it
is unlikely that E. purpurea will produce clinically
relevant interactions with coadministered drugs
through P-gp modulation.
Limitations of our study include the fact that
we chose to administer oral midazolam in lieu of
also administering intravenous midazolam. As
such, it is not possible to compare and contrast
the influence of E. purpurea on intestinal versus
hepatic CYP3A. In addition, we did not perform
an independent phytochemical analysis for
“marker compounds,” such as cichoric acid,
echinacoside, or chlorogenic acid, in the E.
purpurea product used in this study.12 As such, it
is possible that the E. purpurea product we used
differed in alkylamide content compared with
other commercial preparations. Alkylamide
content has been associated with the in vitro
inhibitory potency of E. purpurea.27 In addition,
the product we used was produced with E.
purpurea fresh liquid extract (prepared from
freshly harvested E. purpurea plants), whereas
other Echinacea products may also contain
Echinacea angustifolia root, which has been
shown to inhibit CYP3A4 in vitro.28 Nonetheless,
the observation of a statistically significant
interaction between E. purpurea and midazolam
in this study suggests that the product we used
contained sufficient quantities of CYP3A-
modulating constituent(s).
Results from this study suggest that E. purpurea
is unlikely to significantly alter the disposition of
CYP3A substrates (i.e., protease inhibitors) when
they are administered in combination with a
potent CYP3A inhibitor (i.e., ritonavir). It is
possible, however, that E. purpurea may cause
mild reductions (~25–30%) in the systemic
exposure of CYP3A substrates that are not
routinely coadministered with potent CYP3A
inhibitors; the clinical relevance of such
interactions will be greater in individuals taking
CYP3A substrates whose plasma concentrations
must be maintained above threshold values for
optimal pharmacologic efficacy. Due to the
variable effects of E. purpurea on intestinal versus
hepatic CYP3A activity, as shown by other
investigators,11 the influence of E. purpurea on
the net exposure of a coadministered CYP3A
substrate will likely depend on the CYP3A
extraction ratio of the concurrent drug. Drugs
that are poorly absorbed due to significant
intestinal metabolism through CYP3A may
undergo increased oral bioavailability secondary
to intestinal CYP3A inhibition by E. purpurea.
Conversely, CYP3A substrates with adequate
bioavailability and a low clearance may undergo
increased oral clearance secondary to hepatic
induction of CYP3A by E. purpurea.11
Conclusion
Echinacea purpurea is unlikely to alter the
pharmacokinetics of ritonavir-boosted protease
inhibitors such as the lopinavir-ritonavir combi-
nation assessed in this study. However, patients
with HIV infection frequently take a variety of
drugs in addition to antiretrovirals, many of
which are metabolized—at least in part—by
CYP3A; patients taking these drugs in conjunc-
tion with E. purpurea should be monitored
closely for potential herb-drug interactions.
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